Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 4/20 | 0.46 |
| ▸ | RXRB | P28702 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437592 | 0.83 | TP53 (0.50) | TP53TSHRALDH1A1CA12CA1 | |
| SCHEMBL694974 | 0.79 | MAPT (0.48) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1875943 | 0.78 | LDHA (0.58) | TP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2637326 | 0.78 | TSHR (0.80) | BCL2L1BADTP53TSHRRXRA | |
| SCHEMBL14018385 | 0.78 | TSHR (0.80) | BCL2L1BADTP53TSHRRXRA | |
| SCHEMBL69873 | 0.78 | TSHR (0.80) | BCL2L1BADTP53TSHRRXRA | |
| Terephthalic Acid SCHEMBL9577834 | 0.78 | TSHR (0.80) | BCL2L1BADTP53TSHRRXRA | |
| SCHEMBL10889799 | 0.77 | ESR1 (0.50) | BCL2L1ALDH1A1 | |
| SCHEMBL19461144 | 0.76 | ERCC1 (0.45) | ALDH1A1 | |
| SCHEMBL19466166 | 0.76 | ABCC4 (0.58) | TSHRRXRARXRBALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618159-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2212282-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| US-7361663-B2 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1263726-B1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS INC | 2004-11-04 | — | — | US | disclosed |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. | 2003-05-15 | — | — | US | disclosed |
| EP-1278732-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | Aventis Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1263726-A1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001081310-A1 | 1-AROYL-PIPERIDINYL BENZAMIDINES | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001034567-A1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | BCL2L1 2942/4885BAD 1340/4885TP53 4848/4885 |
| US-20040220171-A1 | 1-Aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | BCL2L1 2940/4885BAD 2991/4885TP53 4808/4885 |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | BCL2L1 1298/4885BAD 436/4885TP53 4059/4885 |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | BCL2L1 2942/4885BAD 1340/4885TP53 4848/4885 |
| US-20020045613-A1 | 1-aroyl-piperidinyl benzamidines | TPSAB1, TPSB2, CMA1 | BCL2L1 2940/4885BAD 2991/4885TP53 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.